These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 17089127

  • 1. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma.
    Ritchie DS, Seymour JF, Grigg AP, Roberts AW, Hoyt R, Thompson S, Szer J, Prince HM.
    Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127
    [Abstract] [Full Text] [Related]

  • 2. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
    Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF.
    J Clin Oncol; 2005 Oct 01; 23(28):7013-23. PubMed ID: 16145068
    [Abstract] [Full Text] [Related]

  • 3. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
    Inamdar KV, Romaguera JE, Drakos E, Knoblock RJ, Garcia M, Leventaki V, Medeiros LJ, Rassidakis GZ.
    Cancer; 2009 Oct 15; 115(20):4727-36. PubMed ID: 19708031
    [Abstract] [Full Text] [Related]

  • 4. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
    Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ.
    Cancer; 2009 Mar 01; 115(5):1041-8. PubMed ID: 19170236
    [Abstract] [Full Text] [Related]

  • 5. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
    Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, Kantarjian HM, O'Brien SM.
    Cancer; 2004 Mar 15; 100(6):1179-85. PubMed ID: 15022284
    [Abstract] [Full Text] [Related]

  • 6. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
    Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M.
    Br J Haematol; 2010 Jul 15; 150(2):200-8. PubMed ID: 20528872
    [Abstract] [Full Text] [Related]

  • 7. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma.
    Evens AM, Winter JN, Hou N, Nelson BP, Rademaker A, Patton D, Singhal S, Frankfurt O, Tallman MS, Rosen ST, Mehta J, Gordon LI.
    Br J Haematol; 2008 Feb 15; 140(4):385-93. PubMed ID: 18162124
    [Abstract] [Full Text] [Related]

  • 8. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J.
    Cancer; 2008 Nov 15; 113(10):2734-41. PubMed ID: 18973182
    [Abstract] [Full Text] [Related]

  • 9. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W.
    J Clin Oncol; 2005 Mar 20; 23(9):1984-92. PubMed ID: 15668467
    [Abstract] [Full Text] [Related]

  • 10. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H, Thomas D, O'Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ.
    Cancer; 2004 Dec 15; 101(12):2788-801. PubMed ID: 15481055
    [Abstract] [Full Text] [Related]

  • 11. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.
    Lefrère F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, Arnulf B, Damaj G, Maillard N, Ribrag V, Janvier M, Sebban C, Casasnovas RO, Bouabdallah R, Dreyfus F, Verkarre V, Delabesse E, Valensi F, McIntyre E, Brousse N, Varet B, Hermine O.
    Leukemia; 2002 Apr 15; 16(4):587-93. PubMed ID: 11960337
    [Abstract] [Full Text] [Related]

  • 12. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H.
    Cancer; 2006 Apr 01; 106(7):1569-80. PubMed ID: 16502413
    [Abstract] [Full Text] [Related]

  • 13. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA, O'Brien S, Thomas DA, Pierce SA, Lam TP, Kantarjian HM.
    Cancer; 2002 Jan 15; 94(2):285-91. PubMed ID: 11900213
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
    van 't Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J, Hagenbeek A, van Putten WL.
    Br J Haematol; 2009 Feb 15; 144(4):524-30. PubMed ID: 19036081
    [Abstract] [Full Text] [Related]

  • 16. [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation].
    Hosono N, Yamauchi T, Nakamura T, Yamashita T, Ueda T.
    Gan To Kagaku Ryoho; 2008 Mar 15; 35(3):533-7. PubMed ID: 18347412
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
    Murali S, Winton E, Waller EK, Heffner LT, Lonial S, Flowers C, Kaufman J, Arellano M, Lechowicz MJ, Mann KP, Khoury HJ, Langston AA.
    Bone Marrow Transplant; 2008 Oct 15; 42(8):529-34. PubMed ID: 18622414
    [Abstract] [Full Text] [Related]

  • 19. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
    Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, Avvisati G, Petrucci MT, Pulsoni A, Leone G, Sica S, Martelli M, Tabilio A, Fioritoni G, Majolino I, Mandelli F.
    Haematologica; 2000 Jan 15; 85(1):52-8. PubMed ID: 10629592
    [Abstract] [Full Text] [Related]

  • 20. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia.
    Xu W, Li JY, Qian SX, Wu HX, Lu H, Chen LJ, Zhang SJ, Lu RL, Sheng RL.
    Leuk Res; 2008 Jun 15; 32(6):930-5. PubMed ID: 18061665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.